Current study results from the report, 'Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans,' have been published. According to recent research from the United States, "Bailey et al. report in this issue of the journal (beginning on page 35) one of the first successful trials of basal cell carcinoma (BCC) prevention."
"Oral alpha-difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of nonmelanoma skin cancer. DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway," wrote C.A. Elmets and colleagues, University of Alabama, Comprehensive Cancer Center (see also …
Its good new for us about new research on non-melanoma skin cancer from University of Alabama Comprehensive Cancer Center.Skin Cancer Treatment in Alabama is really very effective and people are coming through out the world.
ОтветитьУдалить